petrelintide

Petrelintide is a long-acting amylin analog peptide designed for once-weekly subcutaneous administration. It is based on the 36-amino-acid sequence of human amylin and has been chemically modified to enhance stability and prevent fibrillation at neutral pH, allowing for potential co-formulation with other peptides. Petrelintide mimics the effects of endogenous amylin—a hormone co-secreted with insulin by pancreatic beta cells in response to food intake—by activating the amylin receptor. This activation leads to increased satiety (restoring leptin sensitivity), slowed gastric emptying, and reduced postprandial glucagon secretion from the liver, thereby regulating appetite and blood glucose levels. Clinical data suggest that petrelintide can deliver weight loss comparable to GLP-1 receptor agonists but with improved tolerability. It is being developed primarily for obesity/overweight management (with or without type 2 diabetes) and as an adjunct therapy in diabetes care[2][3][4][5][7].

Brand names

petrelintide

Other names

ZP8396ZP-8396ZP 8396petrelintide